TIME Time Finance Plc

 

TIDMTIME 
 
RNS Number : 1343V 
Timestrip PLC 
06 July 2009 
 
Timestrip plc 
("Timestrip" or the "Company") 
 
 
New distribution agreement 
 
 
The Company is delighted to announce further progress with its commercialization 
of TimestripIV, the innovative technology that enables clinicians and patients 
to quickly assess how long a cannula has been in place and thus take appropriate 
action in line with hospital infection control procedures. 
 
 
The Company has appointed Vygon (UK) Limited as the Main Distributor for 
TimestripIV products in the United Kingdom and Ireland. Vygon (UK) Ltd is a 
leading supplier of single-use medical and surgical products, including 
intravenous access devices, to the NHS. Vygon (UK) Ltd is part of The Vygon 
Group of Companies which have supplied the healthcare profession for over 40 
years. 
 
 
TimestripIV will be available to hospitals through the NHS Supply Chain from the 
end of July. Vygon also intends to include TimestripIV as a component in a new 
cannulation pack that will be available in the coming months. In addition, Vygon 
will act as the reseller of TimestripIV to other manufacturers of intravenous 
access devices and cannulation packs, thereby ensuring the widest possible 
availability for the product to the NHS and private hospital groups. 
 
 
Paul Freedman, Joint CEO, Timestrip Plc: "We are delighted to be partnering with 
such a dynamic and professional company as Vygon. They have a significant reach 
into the NHS supply chain and have an outstanding approach to introducing new 
products to the healthcare market. Their agreement to commit significant 
resources to the launch of TimestripIV means that it will have the best possible 
chance of success." 
 
 
Les Davies, Managing Director, Vygon UK: "We have been very impressed by the 
innovative nature of this product and the positive feedback it has received both 
in pilot studies and also from a wider audience of stakeholders in the NHS. 
TimestripIV is a natural fit with our extensive range of intravenous devices. 
Current statistics reveal that in the UK alone there are over 40 million 
venepuncture and cannulation procedures a year and we are confident that our 
proven strength in this market will help the product to achieve its considerable 
potential." 
 
For further information: 
 
 
Paul Freedman, Joint CEO, Timestrip    01462-440700 
 
 
Geoff Nash/Ed Frisby, Finncap     0207 600 1658 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGREAKXDEFNNEFE 
 

Time Finance (LSE:TIME)
Historical Stock Chart
From Jun 2024 to Jul 2024

Time Finance (LSE:TIME)
Historical Stock Chart
From Jul 2023 to Jul 2024